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Abstract
Introduction: Type 1 interferon (IFN)-inducible genes and their inducible products are upregulated in dermatomyositis
muscle. Of these, IFN-stimulated gene 15 (ISG15) is one of the most upregulated, suggesting its possible involvement in the
pathogenesis of this disease. To test this postulate, we developed a model of type 1 IFN mediated myotube toxicity and
assessed whether or not downregulation of ISG15 expression prevents this toxicity.
Methods: Mouse myoblasts (C2C12 cell line) were cultured in the presence of type 1 or type 2 IFNs and ISG15 expression
assessed by microarray analysis. The morphology of newly formed myotubes was assessed by measuring their length,
diameter, and area on micrographs using imaging software. ISG15 expression was silenced through transfection with small
interference RNA.
Results: Type 1 IFNs, especially IFN-beta, increased ISG15 expression in C2C12 cells and impaired myotube formation.
Silencing of ISG15 resulted in knockdown of ISG15 protein, but without phenotypic rescue of myotube formation.
Discussion: IFN-beta affects myoblast differentiation ability and myotube morphology in vitro.These studies provide
evidence that ISG15, which is highly upregulated in dermatomyositis muscle, does not appear to play a key role in IFN-beta-
mediated C2C12 myoblast cell fusion.
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Introduction
Binding of type 1 interferons (IFNs), which include IFN-a and
IFN-b, to type 1 interferon receptor on target cells stimulates the
transcription and translation of a set of genes known as the type 1
IFN-inducible genes. Proteins produced from these genes’
transcripts, such as IFN-stimulated gene 15 (ISG15) and myxo-
virus resistance protein A (MxA), play a role in defending cells
from viral and bacterial infections and are part of the innate
immune system.
Type 1 IFN-inducible genes, including ISG15, are highly
upregulated in muscle [1–6], blood [4,7], and skin [8] of
patients with dermatomyositis (DM), an autoimmune disease
affecting skeletal muscle and other tissues. Endothelial tubulor-
eticular inclusions and the proteins MxA and ISG15 are found
in abundance intracellularly in diseased myofibers, keratinocytes,
and capillaries of DM muscle and skin [3,5,9]. Plasmacytoid
dendritic cells (pDCs), professional type 1 interferon producing
cells, are abundant in DM muscle and skin [3,10,11]. IFN-b
protein in serum [12] and IFN-b transcript in skin [7] are
elevated in DM and correlate with a type 1 interferon gene
expression signature. In endothelial cell culture models,
tubuloreticular inclusions are induced by type 1, but not type
2 (consisting of the sole member IFN-c), IFN exposure [13–16].
In human skeletal muscle cells (HuSK), ISG15 gene and protein
expression are highly induced by IFN-b [5]. Together, these
findings suggest that exposure of relevant cells in culture to type
1 IFN could be a suitable model to study possible mechanisms
of myofiber and capillary injury in DM driven by type 1 IFNs.
In this study therefore, we have used the C2C12 mouse
myoblast cell line to examine the possible effect of type 1 IFNs on
myotube formation. Because ISG15 is one of the most upregulated
genes in DM and ISG15 protein localizes by immunohistochem-
istry to atrophic myofibers [5], we examined its possible role in
IFN-mediated myotoxicity in vitro.
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Results
Type 1 IFNs Upregulate ISG15 in C2C12 Mouse Myoblasts
In previously published studies, ISG15 was upregulated 194-
fold in human DM muscle biopsy samples [5]. We studied a
muscle cell culture line, C2C12 cells, stimulating them with
IFN-a, IFN-b, and IFN-c for 7 days and assessed global
transcriptional responses at Day 4 and Day 7 (manuscript in
preparation). ISG15 gene expression was upregulated on Day 4
114-fold in response to IFN-a, 191-fold in response to IFN-b,
and 11-fold in response to IFN-c (Figure 1A). ISG15’s marked
upregulation by IFN-b was sustained at Day 7 (196-fold) in
contrast to its response to IFN-a that had diminished compared
to Day 4 (30-fold).
Type 1 IFNs Impair the Differentiation of C2C12 Mouse
Myoblasts and Human Skeletal Muscle
These data prompted us to further investigate the role of type 1
IFNs during myoblast differentiation. We initially focused on early
time points (48 h and 72 h) because of the greater uniformity of
early myoblast differentiation. Treatment of cultured C2C12
mouse myoblasts with type 1 IFNs resulted in significant alteration
in the timing of differentiation and in the morphology of new
myotubes, as compared to untreated cells. Untreated cells started
to differentiate before 48 h in low-serum medium, while type 1
interferon treatment impaired myoblast differentiation into
myotubes. Myotube areas (reflecting both mean diameter and
length) at 48 hours were decreased 32% by IFN-b (p,0.0001) and
19% by IFN-a (p,0.0001) compared to untreated myotubes
(Figure 1B). At 72 hours, the inhibitory effect of IFN-b remained
(44% reduction in area; p,0.0001), whereas the inhibitory effects
of IFN-a were no longer present (7%; p= 0.74). These sustained
Figure 1. Effects of type 1 IFNs on mouse C2C12 and humanmuscle cells. (A) IFN-b results in sustained marked expression of ISG15 (196-fold
increased at Day 7). (B) Sustained toxicity of IFN-b on myotube area. (C–E) Dose-dependent effects of IFN-b 10 U/ml and 100 U/ml on myotubes. (C)
Dose-dependent reduction in numbers and lengths of C2C12 myotubes at 48 h and 72 h. Arrows indicate myotubes. (D) Dose-dependent reduction
in C2C12 myotube length, diameter, and area at 72h. (E) Dose-dependent effect of IFN-b on 72 h human skeletal muscle with marked inhibition of
myotube formation at 100 U/ml.
doi:10.1371/journal.pone.0065362.g001
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effects of IFN-b on myotube development, together with
transcriptional data indicating sustained effects of IFN-b on
ISG15 upregulation and recent findings implicating IFN-b in the
pathogenesis of dermatomyositis [8,12], led us to focus further
experiments on IFN-b alone. We therefore extended quantitative
studies on IFN-b’s effect to 96 h and 120 h and observed sustained
impairment in myotube morphology (e.g., 49% decreased area,
p = 0.02, at 120 h; Figure 1B).
We next conducted dose-response studies of IFN-b’s effect on
myotube length, diameter, and area (Figure 1C, D). At 48 h and
72 h, IFN-b at doses of 10 U/ml and 100 U/ml visibly decreased
numbers of myotube formation in a dose-dependent manner, with
the larger dose resulting in fewer and shorter myotubes (Figure 1C).
Quantitative analysis showed similar dose-dependent relationships
on myotube length, diameter, and area (e.g., myotube area
decreased 36% with 10 U/ml and 55% with 100 U/ml, p,0.002;
Figure 1D).
Lastly, we examined human skeletal muscle cell culture and
found dose-dependent marked toxicity of IFN-b, with 100 U/ml
completely preventing myotube formation at 48 h and 72 h
(Figure 1E). Similarly to C2C12, IFN-a was considerably less toxic
to HuSK (data not shown).
Silencing ISG15 does not Prevent IFN-b-mediated
Toxicity for C2C12 Myoblasts
To assess whether the toxic effect of IFN-b on the differentiation
of C2C12 myoblasts was mediated by ISG15, we silenced ISG15
by transfecting C2C12 myoblasts with siRNA against ISG15.
ISG15 protein expression, as assessed by Western blotting, is
highly increased in type 1 IFN-treated HuSK muscle cells in vitro
and in DM patient muscle [2]. We therefore assessed C2C12
ISG15 protein expression by Western blotting at different time
points after the start of IFN-b treatment. A full silencing effect of
ISG15 translation was observed in cells exposed to siISG15 and
treated daily with IFN-b, at 48 and 72 hours after induction of
differentiation, with partial return of ISG15 protein to approxi-
mately 25–50% of baseline levels at later time points (Figure 2A).
We therefore focused our studies on the 72 h and 96 h time points,
reflecting maximal duration of ISG15 silencing (72 h) and the
transition to return of partial ISG15 production (96 h).
ISG15 silencing had no effect on the appearance of IFN-b-
treated cultures (Figure 2B) and left unchanged or even
accentuated IFN-b-mediated reductions in myotube length,
diameter, and area (Figure 2C). At 72 h, IFN-b combined with
siISG15 treatment reduced myotube area 21%, not significantly
different (p = 0.20) than the 10% reduction from IFN-b treatment
alone. At 96 h, myotube area was reduced 45% with siISG15
treatment compared to 53% reduced from IFN-b alone (p = 0.74).
Indeed, at the latest time point, 120 h, siISG15 and IFN-b treated
cells were significantly more impaired (66% myotube area
reduction) than IFN-b treatment alone (49% myotube area
reduction, p= 0.02).These findings suggest that ISG15 does not
mediate early C2C12 IFN-b myotoxicity.
Discussion
Recent studies have identified type1 IFNs or their inducible
gene products as biomarkers of DM [1–9], suggesting a
mechanism of myofiber and capillary injury driven by type 1
IFNs. We therefore developed a cell culture model to explore the
effects of type 1 IFNs on muscle cells.
We found that type 1 IFNs impair myotube differentiation of
both C2C12 mouse myoblasts and human myoblasts. These
findings are consistent with other studies demonstrating toxic and
antiproliferative effects of type 1 IFNs in other cell lineages
(endothelial cells and vascular smooth muscle) [17–21].
Regarding the mechanism of type 1 IFN myocyte toxicity, we
focused on the potential role of ISG15, a gene whose transcript
and protein are highly elevated in human DM muscle [1–6].
ISG15 is a member of the ubiquitin-like proteins family, with
significant sequence homology to ubiquitin. Like ubiquitin, ISG15
is conjugated to many cellular proteins; the conjugation process
requires the conjugating enzymes Ube1L, Ube2L6, and HERC5
as well as a deconjugating enzyme, USP18 [22–25]. Previous
studies indeed demonstrated both the marked increase in free
ISG15 protein as well as numerous ISG15 conjugated proteins in
DM muscle and human skeletal muscle culture [5], suggesting a
potential role as a mediator of IFN-mediated toxicity. We
therefore examined the effect of IFN-a, IFN-b, and IFN-c in the
C2C12 model we developed and demonstrated that IFN-b, but
not IFN-a, or IFN-c, resulted in marked and sustained upregula-
tion of ISG15. The lack of IFN-c upregulation of ISG15 is
explained by its known mechanism of action, as it binds to the
gamma activation sequence (GAS) in promoter regions, and
ISG15 does not contain this GAS element. In contrast, the known
mechanisms of IFN-a and IFN-b involve binding to the interferon-
stimulated regulatory element (ISRE), multiple copies of which are
present in ISG15 [3]. However, as both IFN-a and IFN-b bind to
a common receptor, the more potent and sustained upregulation
of ISG15 by IFN-b is an empirical observation of unknown
mechanism. Regardless of mechanism, we found that ISG15
silencing did not reverse IFN-b mediated toxicity, providing
evidence against ISG15 being a major factor mediating the
myotoxic effects of IFN-b.
Limitations of our studies include the use of an in vitro
immortalized cell line model. Nevertheless, the molecular
responses of this model to IFN-b are consistent with those found
in numerous previously published studies of DM human tissue
(blood, muscle, and skin) [1–12]. It is likely that other type 1 IFN
induced genes are involved in myotoxicity, but the detailed
mechanisms remain to be established. An approach similar to the
one taken here, inhibiting other genes, might yield candidate
mechanisms. However, currently no animal model of dermato-
myositis exists, so that in vivo exploration of these mechanisms will
likely await future development of such a model.
Materials and Methods
Cell Culture and Treatment with type 1 IFNs
Mouse skeletal muscle cells (C2C12; ATCC, Cat. No. CRL-
1772) were cultured in 6-well plates, with growth medium
consisting of DMEM (Atlanta Biologicals, Lawrenceville, GA)
supplemented with 20% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA). Differentiation was initiated 72 h after
seeding, by replacing the growth medium with D-MEM supple-
mented with 2% horse serum (Atlanta Biologicals, Lawrenceville,
GA). At approximately 95% confluence, cells were treated daily
with IFN-a or -b (PBL Interferon Source, Piscataway, NJ), at two
different final concentrations (10 and 100 U/ml per well).
Human skeletal muscle cells (HuSK; ScienCell Research
Laboratories, Cat no. 3500, Carlsbad, CA) were cultured in 6-
well plates and treated with human IFN-b as previously described
[2].
siRNA Transfection
For small interfering RNA (siRNA) experiments, C2C12
myoblasts were transfected 24 h after seeding, when cell density
was approximately 30–50%, with siRNA against ISG15 (Invitro-
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gen, Carlsbad, CA) at the final concentration of 30 nM per well.
Four to six hours after transfection, cells were treated daily with
two different doses (10 and 100 U/ml) of mouse IFN-a or -b (PBL
Interferon Source, Piscataway, NJ); differentiation was induced 48
hours later.
Measurement of Length, Diameter, and Area of Newly
Formed Myotubes
For quantitative morphological analysis, four micrographs were
taken per well, at several time points, 48 h, 72 h, 96 h, and 120 h
from the start of treatment) and for each, the length, diameter and
area of the 10 visually largest myotubes were measured, using
ImageJ 1.44 software (http://rsbweb.nih.gov/ij/, National Insti-
tutes of Health, Bethesda, MD). Statistical testing used nonpara-
metric methods that do not assume Gaussian distributions of the
data (Mann-Whitney tests).
Western Blotting Analysis
Trypsinized cells were lysed in buffer containing 10 mM
HEPES, 10 mM KCl, 1 mM EDTA, 0.1 nM EGTA, 10 mM
DTT, 5 mM MgCl2 and Roche Complete Protease Inhibitor
(Roche Diagnostic, Indianapolis, IN). Homogenates were sonicat-
ed and centrifuged for 10 min at 4uC (10,000 xg), supernatants
were collected and protein contents were measured using BCA
assay (Pierce Biotechnology, Rockford, IL). Samples were diluted
in Loading Buffer 4X and denatured for 5 min at 95uC. Equal
amounts of proteins were electrophoresed on 4–12% NuPage
acrylamide gels (Invitrogen, Carlsbad, CA), and transferred onto
nitrocellulose membranes. Membranes were blocked in Tris
buffered saline with 0.1% Tween 20 (TBS-T) with 5% (wt/vol)
nonfat milk powder and incubated overnight in the same solution
containing rabbit polyclonal anti-ISG15 (Abcam, Cambridge,
MA, cat # 45285; 1:500 dilution), at 4uC, followed by a 1 hr
incubation at RT with secondary antibody (HRP-conjugated goat
anti-rabbit IgG Abcam, Cambridge, MA, Cat #6721, 1:10,000
dilution). Immunoreactivity was detected by SuperSignal West
Pico Maximum Sensitivity Substrate (Pierce Biotechnology, Rock-
ford, IL) 5 min room temperature and exposed to film.
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